This article is more than 5 years old. Information may no longer be current.
Alcon reports 2005 global sales of $4.37 billion
Click Here to Manage Email Alerts
HUNENBERG, Switzerland — Alcon reported total sales for 2005 of $4.37 billion, up 11.6% from $3.91 billion in 2004, the company announced in a press release. Surgical product sales led the company’s growth, posting $2.01 billion in sales for the year, with pharmaceuticals posting $1.77 billion and the consumer eye group reporting $583.9 million, the company said.
Sales were evenly split between the United States and the rest of the world, with U.S. sales of $2.19 billion and international sales of $2.17 billion.
During the fourth quarter, Alcon noted sales of glaucoma products increased 19.7% overall, led by a 37.8% rise in sales of Travatan (travoprost). Sales of the company’s infection/inflammation products rose almost 14% in the quarter, led by fluoroquinolone Vigamox (moxifloxacin). Alcon said Vigamox is the leading ocular anti-infective in the United States, with a 45.1% market share. Four months after its launch, nonsteroidal anti-inflammatory drug Nevanac (nepafenac) has a 19.4% market share in the United States, Alcon said. Ocular allergy medicines, including Patanol (olopatadine), increased sales by 18.3%.
Surgical sales rose 10.7% to $523.5 million in the fourth quarter, Alcon said. IOL sales increased 18.3%, led by the AcrySof ReSTOR and AcrySof Natural IQ IOLs. Refractive revenue declined by 11%, while cataract and vitrectomy system sales increased 7.9%, Alcon said in the release.